ATLANTA--(BUSINESS WIRE)--Capsalus Corp. (OTCBB:WELL) has received a Buy rating from Opus Group Financial, an upgrade from its Speculative Buy recommendation issued last February. The independent financial advisory firm based its new rating on the ongoing roll-out of Capsalus’ expansion plans, highlighted by the acquisition of GeneWize Life Sciences, Inc. and the development and launch of Guava Healthcare, Inc.’s franchising business model. GeneWize Life Sciences (http://www.genewize.com/) is the first beauty and wellness network marketing DNA customized nutritional supplements, skin care and gene modulating weight management products; now as a franchisor, Guava Healthcare (http://www.guavahealthcare.com/) offers customized in-home, non-medical and medical staffing and services to clients across the age spectrum.
